Product Description
Mechanisms of Action: CD37 Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Aptevo
Company Location: SEATTLE WA 98121
Company CEO: Marvin White
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia|Lymphoma
Phase 1: Lymphoma, B-Cell|Lymphoma, Non-Hodgkin|Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia|T-Cell Leukemia|T-Cell Peripheral Lymphoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NCT01644253 | P1 |
Terminated |
Lymphocytic Chronic B-Cell Leukemia|T-Cell Peripheral Lymphoma|Chronic Lymphoid Leukemia|T-Cell Leukemia|Lymphoma, B-Cell |
2020-02-24 |
28% |
2010-019554-41 | P2 |
Completed |
Chronic Lymphoid Leukemia |
2014-12-11 |
|
NCT01188681 | P2 |
Completed |
Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia |
2014-12-01 |
|
NCT01317901 | P1 |
Completed |
Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia|Lymphoma, B-Cell |
2013-04-01 |